Company Description
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.
It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure.
In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson’s disease.
Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Timothy Warbington |
Contact Details
Address: 211 East Osborn Road Phoenix, Arizona 85012 United States | |
| Phone | (480) 399-2822 |
| Website | creativemedicaltechnology.com |
Stock Details
| Ticker Symbol | CELZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001187953 |
| CUSIP Number | 22529Y200 |
| ISIN Number | US22529Y4089 |
| Employer ID | 87-0622284 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy Warbington | Co-Founder, Chairman, President and Chief Executive Officer |
| Donald F. Dickerson MBA | Senior Vice President, Chief Financial Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 23, 2024 | PRER14A | Filing |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 23, 2024 | 424B5 | Filing |
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |
| Oct 4, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 4, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Jul 25, 2024 | 8-K | Current Report |
| Jun 5, 2024 | DEF 14A | Other definitive proxy statements |